| Name | Title | Contact Details |
|---|
Hospital Patient Services is a Phoenix, AZ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
In 2016, OmniGuide Surgical and Domain Surgical were merged, creating an organization focused on providing better outcomes and a safer, more seamless surgical experience. Today, OmniGuide Surgical`s Enhanced Safety Flexible CO2 Laser Fibers and Domain Surgical`s FMX Ferromagnetic Technology are used in the most challenging surgical procedures throughout the world, safely delivering energy resulting in the preservation of healthy tissue. OmniGuide Surgical, based in Lexington, MA, USA, is the leader in flexible fiber CO2 laser technology; providing products that enhance surgical accuracy, access, and control for minimally invasive surgery, laparoscopy, and robotic-assisted surgery. Domain Surgical, located in Salt Lake City, UT, USA, provides a patented ferromagnetic technology designed to provide safety and predictability in select surgical procedures that require cutting, coagulating and sealing tissue.
ConcertoCare is one of the nation`s leading risk-based health care companies focused on providing integrated care for seniors where they are best served: in their homes. ConcertoCare`s programs are designed for seniors with the same core, in-home care model and composed collaboratively with patients. The ConcertoCare model improves overall health quality and outcomes with a proven track record of reducing hospital admits by 47%, readmits by 40% and ER visits by 16% while achieving an increase of 38% in annual wellness visits for the most vulnerable patient populations in the U.S., benefiting patients, payers and provider networks alike. The programs are supported by a combination of in-home medical, behavioral and social services and enhanced via advanced proprietary technologies.
Xenon Pharmaceuticals (NASDAQ:XENE) – a biopharmaceutical company with operations in Vancouver, BC, Canada and Boston, MA, U.S.A. – is committed to delivering innovative medicines to provide a brighter future for patients suffering from neurological disorders. At Xenon, we are advancing an exciting pipeline of neurology-focused therapies, with a particular emphasis on novel treatments for both adult and pediatric patients with epilepsy. XEN496 is currently being evaluated in the Phase 3 “EPIK” clinical trial in young patients with KCNQ2-DEE, a rare and severe form of childhood epilepsy. Late-stage development plans are also underway for our XEN1101 program, building upon the compelling data from the Phase 2b “X-TOLE” study in adult patients with focal epilepsy. We are also proud of the leading-edge science coming out of our discovery labs, with many early-stage research programs underway. In addition to Xenon`s proprietary programs, we have ongoing collaborations with our valued pharmaceutical partners. With a healthy balance sheet to support our growth plans, we continue to build a fully-integrated, premier neuroscience company with strong discovery, development, and commercial operations. Our employees are smart, passionate, dedicated, and driven by their incredibly important work to discover, develop, and deliver new medicines for patients in need. Building and maintaining a respectful, collaborative, inclusive, and productive culture is a priority for us. We are looking for great people who thrive in a fast-paced, dynamic work environment to join our team during this transformative time for Xenon.
A regenerative medicine company based on naturally-produced products from newborn fibroblasts grown in a proprietary bioreactor. Two product families - a proprietary liquid complex of embryonic-like proteins and growth factors` and a human Extracellular Matrix (ECM) material` ExCeltrix..